45. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131:1288—1296.

46. Slovick A, Douiri A, Muir R, Guerra A, Tsioulos K, Hay E et al. Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms. J Allergy Clin Immunol. 2017;139:1830—1839.

47. Mantyla J, Thomander T, Hakulinen A et al. The effect of oral immunotherapy treatment in severe IgE mediated milk, peanut, and egg allergy in adults. Immun Inflamm Dis. 2018;6:307—311.

48. Begin P, Nadeau KC. Changes in peanut-specific T-cell clonotype with oral immunotherapy. J Allergy Clin Immunol. 2015;135:1636—1638.

49. Tanaka Y, Nagashima H, Bando K et al. Oral CD103 (-) CD11b (+) classical dendritic cells present sublingual antigen and induce Foxp3 (+) regulatory T cells in draining lymph nodes. Mucosal Immunol. 2017;10:79—90.

50. Smaldini PL, Trejo F, Cohen JL, Piaggio E, Docena GH. Systemic IL-2/anti-IL-2Ab complex combined with sublingual immunotherapy suppresses experimental food allergy in mice through induction of mucosal regulatory T cells. Allergy. 2018;73:885—895.

51. Okamoto Y, Fujieda S, Okano M, Yoshida Y, Kakudo S, Masuyama K. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy. 2017;72:435—443.

52. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol. 2016;137:339—349.

53. Patterson AM, Bonny AE, ShielsWE, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2016;116:168—170.

54. Johansen P, von Moos S, Mohanan D, Kundig TM, Senti G. New routes for allergen immunotherapy. Hum Vaccin Immunother. 2012;8:1525—1533.

55. Lee SP, Choi SJ, Joe E et al. A pilot study of intralymphatic immunotherapy for house dust mite, cat, and dog allergies. Allergy Asthma Immunol Res. 2017;9:272—277.

56. Hylander T, Larsson O, Petersson-Westin U, et al. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res. 2016;17:10. doi:10.1186/s12931-016-0324-9

57. Aricigil M, Muluk NB, Sakarya EU et al. New routes of allergen immunotherapy. Am J Rhinol Allergy. 2016;30:193—197.

58. Campana R, Moritz K, Neubauer A et al. Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients. Sci Rep. 2017;7 (1):11657.

59. Jones SM, Sicherer SH, Burks AW et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139:1242—1252.

60. Majewska-Szczepanik M, Askenase PW, Lobo FM, Marcinska K, Wen L, Szczepanik M. Epicutaneous immunization with ovalbumin and CpG induces TH1/TH17 cytokines, which regulate IgE and IgG2a production. J Allergy Clin Immunol. 2016;138:262—273.

61. Tordesillas L, Mondoulet L, Blazquez AB, Benhamou PH, Sampson HA, Berin MC. Epicutaneous immunotherapy induces gastrointestinal LAP+ regulatory T cells and prevents food-induced anaphylaxis. J Allergy Clin Immunol. 2017;139:189—201.

62. Passalacqua G, Canonica GW. Local nasal specific immunotherapy for allergic rhinitis. Allergy Asthma Clin Immunol. 2006;2:117—123.

63. Syed A, Garcia MA, Lyu SC et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133:500—510.